Safety, Tolerability and Pharmacokinetics of Lumateperone in Pediatric Patients With Autism Spectrum Disorder

Prior treatment

• Reports suicidal ideation (Type 3, 4 or 5 on the Baseline/Screening version of the C-SSRS) within 6 months prior to Screening, or any suicidal behavior within 2 years prior to Screening, and/or the Investigator assesses the patient to be a safety risk to him/herself or others

Other illness

• Has a primary psychiatric diagnosis other than ASD
• Patients with a history of orthostatic hypotension or who have orthostatic hypotension at Screening
• Has a history of uncontrolled/disruptive behavior in the past 30 days that, in the Investigator's opinion, would preclude the ability to participate in study procedures

Lab values

• History of a clinically significant cardiac disorder and/or abnormal screening ECG or a QT interval corrected for heart rate using Fridericia formula (QTcF) \> 460 msec at Screening

Other

• Clinically significant abnormality within 2 years of Screening that in the Investigator's opinion may place the patient at risk or interfere with study outcome variables

• Male or female patients between 5 to less than 13 years of age
• Primary clinical diagnosis of ASD with symptoms of irritability
• ABC-I subscale score of ≥12 at Screening
• CGI-S score of ≥3 at Screening
• Body mass index (BMI) greater than the 5th percentile according to age- and gender-specific CDC Clinical Growth Charts (2000) at Screening
• Ability to swallow capsules